Your Source for Venture Capital and Private Equity Financings

PreciseDx Secures $20.7 Million Series B

2024-08-21
NEW YORK, NY, PreciseDx, a leading innovator in oncology diagnostics, has raised $20.7 million in Series B funding.
PreciseDx, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for new, morphology-driven disease analysis, announced that it has raised $20.7 million in Series B funding, bringing its total funding to date to $31.5 million. The round was led by Eventide Asset Management (Eventide), which invests in biotech and life science healthcare companies seeking solutions for unmet clinical needs.

Additional participants in the round include Labcorp, Quest Diagnostics, and GenHenn Capital Venture, along with existing investors.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors